Deliver superior customer experiences with an AI-driven platform for creating and deploying cognitive chatbots
Deliver Awesome UI with the most complete toolboxes for .NET, Web and Mobile development
Automate UI, load and performance testing for web, desktop and mobile
A complete cloud platform for an app or your entire digital business
Detect and predict anomalies by automating machine learning to achieve higher asset uptime and maximized yield
Automate decision processes with a no-code business rules engine
Optimize data integration with high-performance connectivity
Connect to any cloud or on-premises data source using a standard interface
Build engaging multi-channel web and digital experiences with intuitive web content management
Personalize and optimize the customer experience across digital touchpoints
Build, protect and deploy apps across any platform and mobile device
2018 will be a year of change for the pharmaceutical industry. In this guest post, read about some of the challenges we can expect and one way to solve them.
The pharmaceutical industry is facing a multitude of political, regulatory and financial uncertainties in and beyond 2018. But there’s one thing I know for sure about pharma’s morphing business model: it’s that patients are playing a growing role in the industry’s future well-being. That is, if the industry can meet health consumers where they want to be met.
Patients want more communication and support from pharma companies, a new study from Accenture found. In fact, over one-third of patients tell their health care providers about pharma patient-service programs: this chart from Accenture’s study illustrates the top seven ways providers hear or learn about patient services offered by pharma companies.
Patients want more services from pharma companies, a topic I recently discussed in a paper for Progress, The Future of Consumer Health Engagement in Pharma Enabled Through the Cloud. Several market forces are fostering the opportunity for pharma and life science companies to more closely engage with patients, leveraging the enterprise health cloud.
Patients are taking their health and healthcare into their own hands in a growing DIY, self-service culture. This is particularly pronounced among Millennials, but advancing, too, among patients who want to more effectively manage chronic conditions in partnership with clinicians and health care product suppliers.
Patients, now health consumers, also expect respect: via the best customer service experience they can recall. Enchantingly-designed user experiences create new expectations from other consumer touchpoints – including health care interactions. This expectation is especially acute when the patient sees herself as the payor: for high-cost specialty drugs, and as health plan members exposed to high-deductibles and coinsurance shares for prescription drugs and therapies.
Feeling respected, in fact, has a hard return-on-investment: Altarum Institute’s research found that patients dealing with diabetes were half as likely to be adherent to medication when they did not feel respected by their health providers.
Consumers also lack trust with pharmaceutical companies when it comes to being a trusted source of health information. Compared with hospitals and doctors, the most trusted sites for health information, pharma companies rank last, via dotHealth’s survey.
Healthcare suppliers that put on design-thinking hats and prioritize consumers’ experiences with their personal health care will curry favor with patients who are growing their health care consumer and patient self-care muscles.
Central to this smart patient paradigm is information – not just data points generated via a wearable devices on a wrist, or lab test results — but actionable advice based on a person’s own health-and-life-flows.
Increasingly, data that’s important for picturing the full view of a person’s daily life will be generated beyond the electronic health record feeds. Data will flow from a patient’s home via Internet of Things-connected appliances and sensors, personal digital assistants like the Echo Dot (the top-selling electronic device during Amazon’s 2017 holiday gift-giving season), and mobile devices.
How can pharma and providers connect with this promise? One key technology strategy is to work through a versatile enterprise health cloud (EHC) to corral, mash up, and analyze data, providing actionable advice and ‘nudges’ that consumers can use to maintain and improve their health. EHCs can simplify interoperability – a huge challenge for healthcare suppliers and providers – liberating data to be “liquid” and move into applications. EHCs also streamline development allowing new apps and tools to quickly reach patients’ hands for clinical trials and self-care.
Read more about enterprise health clouds in my whitepaper for Progress, highlighting how using real-world evidence for patients with MS and IBD helps people better manage their conditions. Furthermore, leveraging a health cloud can simplify development at the backend, lowering costs and fast-tracking delivery of apps and tools that patients need sooner, not later.
Adopting this approach can result in a Triple Win for pharmaceutical and life science companies, healthcare providers, and most importantly patients – on the road to achieving the Triple Aim.
Download the Whitepaper
Jane is a health economist, advisor and trend-weaver to organizations at the intersection of health, technology and people. Jane founded THINK-Health after working with health care consultancies in the US and Europe. Jane’s clients span the health/care ecosystem: technology, pharma and life sciences, providers, plans, retail, financial services and consumer goods. She founded the Health Populi blog in 2007. Jane holds an MA (Economics) and MHSA (Health Policy) from University of Michigan.
Copyright © 2018 Progress Software Corporation and/or its subsidiaries or affiliates.
All Rights Reserved.
Progress, Telerik, and certain product names used herein are trademarks or registered trademarks of Progress Software Corporation and/or one of its subsidiaries or affiliates in the U.S. and/or other countries. See Trademarks for appropriate markings.